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A B S T R A C T
Altered reproductive hormone levels have been associated with the pathophysiology of depressive disorders and
this risk may be imparted by their modulatory eﬀect upon hippocampal structure and function. Currently it is
unclear whether altered levels of reproductive hormones are causally associated with hippocampal volume re-
ductions and the risk of depressive disorders. Here, we utilize genome-wide association study (GWAS) summary
statistics from a GWAS focusing on reproductive hormones, consisting of 2913 individuals. Using this data, we
generated polygenic risk scores (PRS) for estradiol, progesterone, prolactin and testosterone in the European
RADIANT cohort consisting of 176 postpartum depression (PPD) cases (100% female, mean age: 41.6 years old),
2772 major depressive disorder (MDD) cases (68.6% female, mean age: 46.9 years old) and 1588 control par-
ticipants (62.5% female, mean age: 42.4 years old), for which there was also a neuroimaging subset of 111
individuals (60.4% female, mean age: 50.0 years old). Only the best-ﬁt PRS for estradiol showed a signiﬁcant
negative association with hippocampal volume, as well as many of its individual subﬁelds; including the mo-
lecular layer and granule cell layer of the dentate gyrus, subiculum, CA1, CA2/3 and CA4 regions. Interestingly,
several of these subﬁelds are implicated in adult hippocampal neurogenesis. When we tested the same estradiol
PRS for association with case-control status for PPD or MDD there was no signiﬁcant relationship observed.
Here, we provide evidence that genetic risk for higher plasma estradiol is negatively associated with hippo-
campal volume, but this does not translate into an increased risk of MDD or PPD. This work suggests that the
relationship between reproductive hormones, the hippocampus, and depression is complex, and that there may
not be a clear-cut pathway for etiology or risk moderation.
1. Introduction
The hippocampus, like the rest of the brain, changes in volume
throughout the human lifespan and is subject to factors such as age
(Daugherty et al., 2016), psychiatric health (Harrisberger et al., 2015)
and altered circulating endogenous factors, such as hormones (Barth
et al., 2016). The hippocampus is not a homogeneous structure and is
composed of multiple subﬁelds, each with a diﬀerent cellular makeup,
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function and associated circuitry (Knierim, 2015). Cellular mediators of
hippocampal volume changes include altered cell death, cell size, and
branching of both neurons and astroglia (Czéh and Lucassen, 2007).
Additionally, adult hippocampal neurogenesis (AHN) provides a unique
region-speciﬁc mechanism contributing to variability in the volume and
plasticity of the dentate gyrus, speciﬁcally (Toda and Gage, 2018).
Research has shown that the endocrine system is partly involved in
the regulation of hippocampal volume and function, indicating roles for
estrogens (i.e. estradiol), androgens (i.e. testosterone), progestogens
(i.e. progesterone) and peptide hormones (i.e. prolactin) (Galea et al.,
2013). A variety of cross-sectional, intervention and longitudinal stu-
dies have shown that these circulating reproductive hormones often
correlate with hippocampal volume (Barth et al., 2016; Bayer et al.,
2013; Braden et al., 2017; Panizzon et al., 2018; Seiger et al., 2016).
The mammalian hippocampus has the potential to be a direct target of
reproductive hormones as it expresses the receptors necessary for signal
transduction, namely the estrogen receptors 1 and 2, the androgen re-
ceptor, progesterone receptor and prolactin receptor (Cabrera-Reyes
et al., 2017; Meﬀre et al., 2013; Shughrue and Merchenthaler, 2000;
Tsai et al., 2015). In the hippocampus, downstream signaling pathways
of these receptors have the potential to drive volume changes through
their known eﬀects on AHN, dendritic morphology and the survival of
neurons (Galea et al., 2013; Mahmoud et al., 2016).
The volume of the hippocampus and its subﬁelds have been linked
to a wide range of neurological and psychiatric disorders. Reduced
hippocampal volume is observed in anxiety, schizophrenia, Alzheimer’s
disease, and the aged brain in general (Arnold et al., 2015; Daugherty
et al., 2016; van Erp et al., 2016; Hibar et al., 2016; Schoenfeld et al.,
2017; Schuﬀ et al., 2009). A loss of hippocampal volume is a commonly
reported feature of depressive disorders (Campbell et al., 2004;
Schmaal et al., 2016; Sheline et al., 1996) and is not only associated
with the presence of the disease, but volume reductions often correlate
with increased disease severity or recurrence (Schmaal et al., 2016;
Treadway et al., 2015). It is hypothesized that these volume reductions
mediate disturbances in cognitive function (e.g. negative aﬀect, rumi-
nating thoughts) which in turn, increase risk for depressive disorders
(MacQueen and Frodl, 2011). In addition, individual hippocampal
subﬁelds exhibit independent volumetric changes in a variety of con-
texts. For example, atrophy of the dentate gyrus and cornu ammonis
regions is commonly observed in major depressive disorder (MDD)
(Huang et al., 2013) and schizophrenia (Haukvik et al., 2015), but only
schizophrenia patients exhibit smaller subiculum regions (Haukvik
et al., 2015).
Changes to circulating reproductive hormones have also been linked
to the development of depressive disorders in a wide range of human
studies (Balzer et al., 2015; Faron-Górecka et al., 2013; Holsen et al.,
2011; Schiller et al., 2015; Zarrouf et al., 2009). Interestingly, females
have an almost two-fold greater risk of developing MDD relative to men
(Bromet et al., 2011; Kessler et al., 1993), which is thought to be in part
due to hormonal diﬀerences and the prevalence of reproductive-related
depressive disorders such as postpartum depression (PPD) (Kuehner,
2017). Due to the aforementioned link between reproductive hormones
and the hippocampus, this brain region is a promising mediator linking
diﬀerences in reproductive hormones to risk of depression. For in-
stance, in the peripartum period, alongside an increased risk of de-
pression diagnosis and robust hormonal changes (Pařízek et al., 2014;
Schock et al., 2016; Stuebe et al., 2015), there are observable altera-
tions to hippocampal volume in rodents, which return to normal in the
weeks following parturition (Galea et al., 2000).
Previous studies have mainly focused on the correlation between
reproductive hormones and whole hippocampal volume; testing the
relationship at a single point in time (Barth et al., 2016; Panizzon et al.,
2018). Although such studies are insightful, they are limited for three
key reasons. Firstly, with correlations alone, it is not possible to discern
whether reproductive hormones are causally aﬀecting hippocampal
volume, or whether reproductive hormones and hippocampal volume
are impacted by an independent environmental factor (e.g. diet or
stress). Secondly, as reproductive hormones are highly dynamic, it can
be diﬃcult, particularly in smaller studies with single measurements, to
generate a stable quantitative measure that adequately captures inter-
individual variation in hormone levels necessary to assess correlations
with the hippocampus. Finally, until now, only whole hippocampal
volumes have been assessed, but as certain areas of the hippocampus
contain stem cells that give rise to new mature neural cells during AHN,
it would be beneﬁcial to evaluate individual subﬁeld volumes in order
to test whether the ‘neurogenic niches’ mediate volume diﬀerences in
response to reproductive hormones, or whether it is mediated by other
areas of the hippocampus.
To address these limitations, we employed a Mendelian randomi-
zation design, which uses genetic information to infer the presence of a
causal relationship between two traits. We tested whether polygenic
risk scores (PRSs) for reproductive hormones predict right or left hip-
pocampal volumes; hippocampal subﬁeld volumes; and subsequently
MDD or PPD case-control status. This approach utilizes hormone-spe-
ciﬁc PRSs as stable genetic predictors of inter-individual variation in
reproductive hormone levels. To achieve this, we used genome-wide
association study (GWAS) summary statistics from 2906 individuals
within the TwinsUK cohort, which has previously identiﬁed single nu-
cleotide polymorphisms (SNPs) associated with circulating re-
productive hormones, including estradiol, testosterone, progesterone
and prolactin (Ruth et al., 2016). To identify links with hippocampal
volume and depressive disorders we used the European RADIANT co-
hort consisting of 176 PPD cases, 2772 MDD cases and 1588 control
participants, for which there is also a neuroimaging subset of 111 in-
dividuals. We identiﬁed the best combination of SNPs from a range of p-
value thresholds obtained from each reproductive hormone GWAS, that
predicted right or left hippocampal volume in our neuroimaging
sample. Next, we tested the eﬀect of this best-ﬁt PRS on the 12 hip-
pocampal subﬁeld volumes. As these 111 individuals represented a
subset of the larger depression case-control study, our ﬁnal aim was to
test whether this best-ﬁt PRS for predicting hippocampal volumes,
further predicted PPD or MDD in the full RADIANT cohort.
2. Materials and methods
2.1. RADIANT sample
RADIANT is an umbrella term for three studies which sought to
understand genetic risk for MDD and factors aﬀ ;ecting response to
antidepressant treatments (Lewis et al., 2010); this comprised of the
Depression Network (DeNT) study (Farmer et al., 2004), the Depression
Case-Control (DeCC) study (Cohen-Woods et al., 2009) and the
Genome-Based Therapeutic Drugs for Depression (GENDEP) study
(Uher et al., 2009). As the DeNT study was composed of sibling pairs,
only one sibling from each family were randomly included in genetic
studies (Lewis et al., 2010). The DeCC and DeNT studies only recruited
individuals who had experienced recurrent depression. While the
GENDEP study did not aim to solely recruit recurrent depression cases,
77.3% of cases were in fact recurrent. Therefore, the entire RADIANT
cohort contains a majority of recurrent depression cases (94.6%). All
participants were interviewed using the Schedules for Clinical Assess-
ment in Neuropsychiatry (SCAN) interview (Wing et al., 1990) focusing
on their two most severe depressive episodes (if applicable). Partici-
pants were excluded if they, or a ﬁrst-degree relative, had ever ex-
perienced mania, hypomania, bipolar disorder, schizophrenia, schizo-
aﬀective disorder, intravenous drug dependence, substance-induced
mood disorder or mood disorders secondary to medical illness or
medication. A total of 2772 MDD cases, 176 PPD cases and 1588 un-
aﬀected controls were available from these studies for the work out-
lined here (Table 1).
Major depressive disorder cases: Participants were classiﬁed as MDD
cases if they had experienced at least one episode of major depression of
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at least moderate severity as deﬁned by the Diagnostic and Statistical
Manual of Mental Disorders 4th edition operational criteria (DSM-IV)
(American Psychiatric Association, 1994) or the International Classiﬁ-
cation of Diseases 10th edition operational criteria (ICD-10) (World
Health Organization, 1992) for unipolar depression. For the purpose of
this study we excluded MDD patients who met further criteria for PPD,
as we considered these individuals separately. MDD cases were 68.6%
female, with an age range 18–67 (mean= 46.9, S.D.= 12.3).
Postpartum depression cases: From the MDD cases identiﬁed within
RADIANT (where data were available), cases of PPD were identiﬁed
using the list of threatening experiences questionnaire (LTE-Q). The
LTE-Q is a 12-term self-reported questionnaire which measures the
occurrence of stressful life events in the 6 months prior to depression
onset, to which childbirth has been added (Brugha and Cragg, 1990;
Farmer et al., 2004). PPD cases were identiﬁed as females who had
experienced either of their two most severe major depressive episodes
within 6 months of childbirth. PPD cases were 100% female, with an
age range of 20–67 (mean=41.6, S.D.= 9.5).
Control participants: Control participants were screened using a
modiﬁed version of the Past History Schedule (McGuﬃn et al., 1986)
for any psychiatric disorder throughout their life. They were excluded if
they, or a ﬁrst-degree relative had suﬀered from depression or any other
psychiatric disorder. Control participants were 62.5% female, with an
age range of 18–89 (mean=46.9, S.D.= 12.3).
Neuroimaging subset: For a subset of the participants described
above (N=111), neuroimaging data was available. Demographics of
participants with both genotype and neuroimaging data are described
in Table 1. This subset was 67% female with an age range of 26–66
years old (mean=50.0, S.D.= 8.1). 58% of the neuroimaging cohort
were depressed cases (either MDD or PPD) and all had experienced
recurrent depression. 44% had taken pharmacological antidepressants
in the 6 months preceding the MRI scan. The majority of the cohort
were righthanded (94%). In addition to the exclusion criteria described
above, participants were excluded from neuroimaging analysis if they
had previously experienced any severe head trauma, neurological
condition or any other contraindications to magnetic resonance scan-
ning.
2.2. RADIANT genetic data
Genotyping data from the RADIANT cohort was already available
and have been used in previous publications (Lewis et al., 2010).
Genomic DNA was extracted from blood and buccal swabs as described
previously (Freeman et al., 2003). DNA samples were genotyped using
the Illumina Human610-Quad bead chip (Illumina, Inc., San Diego, CA,
USA) at the Centre National de Genotypage (Evry Cedex, France).
Single nucleotide polymorphism (SNP) information was available as
PLINK ﬁles (Purcell et al., 2007).
2.3. RADIANT MRI data
MRI data had been collected from a subset of RADIANT, as de-
scribed previously (Cole et al., 2011, 2013). Magnetization-Prepared
Rapid Gradient Echo (MP-RAGE) T1-weighted scans were acquired
using a 1.5 T General Electric Signa MR Imaging System (General
Electric, Milwaukee, Wisconsin, USA) from participants in the sagittal
plane using the parameters: echo time = 3.8 ms, repetition time =
8.592 ms, inversion time = 1000 ms, ﬂip angle = 8°, voxel dimensions
= 0.939 × 0.937 ×1.2 mm, matrix size 192 × 192, ﬁeld of view =
240, slice thickness = 1.2 mm, number of slices = 180.
All T1-weighted images were visually inspected for motion artefact,
wrap-around and grey/white contrast; no data were excluded.
Automated whole brain segmentation, cortical reconstruction and
hippocampal subﬁeld segmentation were carried out using FreeSurfer
v6.0 (Massachusetts General Hospital, Harvard Medical School; http://
surfer.nmr.mgh.harvard.edu) (Fischl et al., 2002; Iglesias et al., 2015).
Hippocampal subﬁeld volumes were visually inspected and no manual
edits were necessary. Volumes were also assessed so that outliers could
be identiﬁed, although no data were excluded based on these measures.
The hippocampal subﬁelds identiﬁed using this segmentation method
and included in this study are as follows: parasubiculum, presubiculum,
subiculum, cornu ammonis 1 (CA1), cornu ammonis 2/3 (CA2/3),
cornu ammonis 4 (CA4 or hilus), granule cell layer of the dentate gyrus,
molecular layer of the dentate gyrus, ﬁmbria, hippocampal-amygdala-
transition area (HATA), hippocampal tail and hippocampal ﬁssure. All
subﬁelds represent regions of grey matter except for the hippocampal
ﬁssure which is a sulcus residing between the dentate gyrus and sub-
iculum.
2.4. Polygenic risk scoring
A polygenic risk score (PRS) is a number which represents an in-
dividual’s genetic load of risk alleles for a certain base trait. Here we
created PRSs for estradiol, progesterone, prolactin and testosterone
separately for each individual in the RADIANT cohort. PRSs for each
reproductive hormone were generated using summary statistics from
the largest GWAS for plasma reproductive hormones to-date, consisting
of 2906 individuals from the Twins UK cohort (Ruth et al., 2016). This
GWAS used a sample consisting of predominantly female participants,
and excluded individuals undergoing any hormonal therapies. The
original GWAS analysis took into account the age, sex, BMI, stage of
menstrual cycle and menopausal status of the participants.
PRSice version 1.25 software was used to implement a pipeline of
processes common in PRS creation (Euesden et al., 2015). Firstly, SNPs
present in only the base GWAS or target RADIANT cohort were re-
moved. Ambiguous (A/T or C/G) SNPs were also removed. SNPs in
linkage disequilibrium (r2> 0.1) were removed using a process called
clumping, leaving a single SNP in each 250 kb LD window with the
smallest p-value from the GWAS. Clumping was preferred over pruning
in order to retain SNPs across the entire genome. The remaining SNPs
were used to calculate PRSs for eight p-value thresholds (0.001, 0.01,
0.05, 0.1, 0.2, 0.3, 0.4 and 0.5). At each p-value threshold, the SNPs
that fell below this threshold in the GWAS summary statistics were
identiﬁed, and the number of risk variants (0, 1 or 2) that an individual
carried was multiplied by the logarithm of the odds ratio for that var-
iant. The sum of all these values gives the PRS for an individual and the
process is repeated for all the individuals in the cohort and for all
hormones.
Table 1
Demographic details of the neuroimaging subset and depressed patients and
controls in the whole RADIANT cohort.
Neuroimaging
subset
Entire RADIANT cohort
Control PPD MDD
N 111 1588 176 2772
Female (N, %) 67 (60.4) 993 (62.5) 176 (100) 1901
(68.6)
Age (mean, SD) 50.0 (8.1) 42.4 (13.0) 41.6 (9.5) 46.9
(12.3)
Depressed (N, %) 58 (47.7) – – –
Antidepressants (N,
%)
44 (39.6) – – –
Handedness (N, %) – – –
Right 94 (84.7) – – –
Left 13 (11.7) – – –
Ambidextrous 3 (2.7) – – –
Abbreviations: Antidepressants: Has taken antidepressant drugs within the past
6 months; PPD: postpartum depression; MDD: major depressive disorder.
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2.5. Statistical analyses
2.5.1. PRSs and hippocampal volumes
Left and right whole hippocampus and hippocampal subﬁeld vo-
lumes were checked for normality using histograms and Kolmogorov-
Smirnov and Shapiro-Wilk normality tests (Vetter, 2017), with non-
normal volumes undergoing log-transformation. Subsequently, volumes
were adjusted for intracranial volume, sex, age and depression case-
control status by taking the standardized residuals (z-scores) using SPSS
v.24. The eﬀects of handedness in the whole cohort, and current anti-
depressant use (last 6 months) amongst depressed cases, was tested, and
found not to signiﬁcantly aﬀect either right or left hippocampal vo-
lumes (p>0.05).
We ﬁrst tested the relationships between PRSs for each reproductive
hormone, and either adjusted left or right hippocampal volume, using
regressions in PRSice (Euesden et al., 2015). In each regression we in-
cluded seven population covariates to correct for population structure.
These population covariates were the top seven components derived
using multi-dimensional scaling in PRSice. We tested the predictive
power of PRSs derived from SNPs under eight p-value thresholds (p =
0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5), in order to determine the
optimal p-value threshold and “best ﬁt” PRS for each hormone and
hemisphere combination. For each hormone and hemisphere combi-
nation, we corrected for the number of p-value thresholds tested using
the Benjamini-Hochberg correction (Benjamini and Hochberg, 1995)
and a false discovery rate of 10%.
Where a PRS for a reproductive hormone explained a signiﬁcant
proportion of the variance in either whole left/right hippocampal vo-
lume, we tested whether the same best ﬁt PRS predicted the volume of
its 12 constituent subﬁelds. This was again performed using PRSice
software, with the same seven population covariates, as described
above. We corrected for the number of subﬁelds tested using the
Benjamini-Hochberg correction with a false discovery rate of 10%.
2.5.2. PRS and depression case-control status
Lastly, once we had identiﬁed a hormone-related PRS which sig-
niﬁcantly predicted hippocampal volume, we tested whether the same
PRS was associated with PPD or MDD case-control status in the wider
RADIANT cohort. Binary logistic regressions, including sex-stratiﬁed
regressions were performed for each depression subtype in PRSice,
covarying for seven population covariates, derived using multi-dimen-
sional scaling in PRSice, with sex included as a covariate where ap-
propriate (i.e. when both males and females were included in the same
analysis).
3. Results
3.1. Polygenic risk for circulating estradiol is associated with whole
hippocampal volume
We created PRSs for plasma estradiol, testosterone, progesterone
and prolactin at eight p-value thresholds and tested for their association
with either right or left whole hippocampal volume. After correcting for
multiple p-value thresholds, only the PRS for estradiol was found to be
signiﬁcantly associated with whole hippocampal volume (Table 2). The
best-ﬁt estradiol PRS (using pthresh = 0.1 for both hemispheres) was
negatively associated with both right (B =−2498.209, SE = 919.795,
p = 0.008, R2 = 0.062) and left (B =−2528.269, SE = 928.911, p =
0.008, R2 = 0.064) hippocampal volumes, and survived our multiple
testing criteria (q< 0.1) (Table 2, Fig. 1). The best ﬁt PRSs for pro-
lactin, testosterone and progesterone were not signiﬁcantly associated
with either right or left whole hippocampal volume.
3.2. Polygenic risk for circulating estradiol is associated with hippocampal
subﬁelds
Next, we investigated the association between the best-ﬁt estradiol
PRS and hippocampal subﬁeld volumes. As with the whole hippo-
campus, the estradiol PRS was associated with the volume of multiple
hippocampal subﬁelds (Table 3). After multiple testing correction, the
estradiol PRS was signiﬁcantly associated with the right and left sub-
iculum, CA1, molecular layer of the dentate gyrus, granule cell layer of
the dentate gyrus, CA2/3 and CA4 regions (Table 3). It was also uni-
laterally associated with the volume of the left hippocampal tail and
right hippocampal ﬁssure. A graphical representation of the associa-
tions between the estradiol PRS and all hippocampal subﬁeld volumes
can be observed in Fig. 2. For all signiﬁcant relationships, a PRS in-
dicative of higher estradiol levels was associated with a reduced vo-
lume.
3.3. Polygenic risk for circulating estradiol does not predict depression case-
control status
Finally, we tested whether the best-ﬁt PRS for estradiol levels,
identiﬁed above, predicted the risk of depressive disorders. The estra-
diol PRS was not associated with PPD case-control status or MDD case-
control status, including in sex-stratiﬁed analyses (p> 0.05; Table 4).
4. Discussion
This study sought to better understand the relationship between
circulating reproductive hormones and hippocampal volume via the
application of polygenic epidemiology, whereby we estimated inter-
individual variation in hormone levels based on genetic data, and tested
how this aﬀected hippocampal subﬁeld volumes. We further in-
vestigated whether the same polygenic signature was associated with
depressive disorders. Our results demonstrate a negative association
between polygenic risk for estradiol levels and whole hippocampal
volume, as well as the volume of many of its constituent subﬁelds.
However, this polygenic risk score did not predict the occurrence of
depressive disorders. Previous literature has linked estradiol levels to
whole hippocampal volume in humans, but this is the ﬁrst to infer
causality via polygenic scoring.
The hippocampus is a major target of estrogens in the brain due its
high density of estrogen receptors which have the capacity to inﬂuence
hippocampal volume through multiple actions, including altered gene
expression, diﬀerential methylation of estrogen-responsive genes or by
rapid-non genomic signaling pathways (Duarte-Guterman et al., 2015;
Guintivano et al., 2014; Sárvári et al., 2015; Soma et al., 2018). Our
results reveal an enrichment of estradiol’s eﬀect on ‘neurogenic regions’
of the hippocampus, namely the granule cell layer and molecular layer
of the dentate gyrus. This suggests that polygenic risk for estradiol le-
vels may confer some of its long-term inﬂuences on hippocampal vo-
lumes via moderating AHN. Changes in AHN have been associated with
volumetric changes in the CA1 in rodents due to altered dendritic
branching (Schoenfeld et al., 2017), which could feasibly also impact
the CA4 region due to the presence of mossy ﬁbers from dentate gyrus
granule cells (Scharfman and Myers, 2013). In general, rodent studies
indicate a proliferative eﬀect of estradiol on dentate gyrus neural stem
cells, but the majority of these studies focus on the very short-term
eﬀects of large changes in estradiol (Mahmoud et al., 2016). Therefore,
it is unclear what impact small, long-term diﬀerences in estradiol may
have on the neurogenic potential of the hippocampus.
In the context of previous research, our ﬁndings support reports
which have revealed an association between higher estradiol levels and
smaller hippocampal volumes (Heijer et al., 2003; Seiger et al., 2016).
It also agrees with the observation of reduced hippocampal volume
during pregnancy in rats, when estradiol, alongside other sex hor-
mones, is elevated (Galea et al., 2000; Rolls et al., 2008). However, they
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are in contrast to other studies which have shown that higher estradiol
concentration is associated with larger hippocampal volumes and pro-
pose a neuroprotective eﬀect of estradiol (Barth et al., 2016; Bayer
et al., 2013; Galea et al., 2013; Kesler et al., 2004). This discrepancy
could be due to a number of diﬀerent reasons. For example, the
dynamic and acute eﬀects of estradiol, which are more commonly
studied, may be diﬀerent to the more chronic, stable, and possibly
lifetime eﬀects captured by polygenic risk scores used in this study.
Indeed, many of these studies quantiﬁed hippocampal volume in the
post-menopausal period, following estradiol supplementation or
Table 2
Table showing the results of regressions that tested the predictive ability of best-ﬁt PRS for all reproductive hormones on left and right whole hippocampal volumes.
Hippocampus Optimal p-value threshold nSNPs p-value q-value R2 β SE
Estradiol
Right 0.1 27389 0.008 *0.051 0.062 −2498.209 919.795
Left 0.1 27389 0.008 *0.040 0.064 −2528.269 928.911
Progesterone
Right 0.001 275 0.120 0.286 0.022 −112.957 72.091
Left 0.01 2340 0.072 0.253 0.030 −370.014 203.569
Prolactin
Right 0.01 2520 0.339 0.735 0.008 370.970 386.164
Left 0.4 54198 0.055 0.176 0.034 5977.305 3083.026
Testosterone
Right 0.05 9953 0.096 0.543 0.025 −1274.616 758.934
Left 0.05 9953 0.138 0.586 0.020 −1148.102 768.731
The optimal threshold is deﬁned as the p-value threshold for the group of SNPs which produces the best-ﬁt PRS for each regression. Whole hippocampal volume was
corrected for intracranial volume, age, sex and depression status. All regression analyses include seven population covariates, derived from multidimensional scaling,
to control for population stratiﬁcation. Associations which survive FDR corrections are indicated with *. Abbreviations: PRS: polygenic risk score; nSNPs: number of
SNPs included in the optimal PRS; p-value: uncorrected p-value; q-value: FDR-corrected p-value; R2: amount of variance explained by the respective optimal PRS; β:
regression coeﬃcient; SE: standard error.
Fig. 1. A&B) Output from PRSice displaying the results of regressing the estradiol PRS against the (A) left and (B) right hippocampal volume at the range of p-value
thresholds tested (x-axis). A combination of SNP information under p=0.1 signiﬁcantly best predicted both left and right hippocampal volumes. Variance explained
(R2) is indicated on the y-axis and uncorrected p-values are indicated above each bar. C&D) Scatterplots demonstrating signiﬁcant negative correlations between the
best-ﬁt PRS for estradiol levels (z-scores; adjusted for 7 population covariates derived from multidimensional scaling to control for population stratiﬁcation) and
whole hippocampal volumes (z-scores; adjusted for intracranial volume, age, sex, case-control status) for the (C) left and (D) right hemispheres. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article).
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alongside the menstrual cycle. Alternatively, as many previous studies
have employed in vitro or animal model systems to draw conclusions
about estradiol’s eﬀects, it may be the case that estradiol has diﬀerent
eﬀects in vivo in humans. Finally, the majority of human studies con-
ducted have focused on the impact of estradiol in either elderly, disease
or medicated states. Therefore, it is diﬃcult to discern what impact
naturally occurring long-term diﬀerences in endogenous estradiol levels
could have on the hippocampus.
Future research will be needed to better understand the diﬀerences
in estradiol’s acute and chronic actions in a variety of ages. Diﬀerent
stages of the lifespan are characterized by large changes in estradiol
levels, including puberty, pregnancy and the menopause. Therefore,
future work should aim to determine how applicable these ﬁndings are
to these diﬀerent contexts. Finally, this result does not necessarily reject
the potential neuroprotective eﬀects of estradiol in the menopause or in
neurodegenerative diseases. In these cases, exogenous estradiol is used
to rectify large deﬁcits in endogenous estradiol which would not be
present in the study population used here (Raz et al., 2004). Ad-
ditionally, many of the beneﬁts of exogenous estradiol in neurogen-
erative diseases are independent of hippocampal volume changes
Table 3
Table showing the results of regressions that test the predictive ability of best-ﬁt
PRS for estradiol, on hippocampal subﬁeld volumes.
Subﬁeld Uncorrected p-
value
q-value R2 β SE
Right hippocampus
CA1 0.026 *0.063 0.043 −2120.714 941.310
CA2/CA3 0.051 *0.087 0.035 −1870.666 945.199
CA4 0.009 *0.034 0.060 −2451.741 919.490
Granule cell layer 0.010 *0.034 0.058 −2398.323 916.184
Molecular layer 0.004 *0.034 0.068 −2690.309 912.037
Subiculum 0.011 *0.034 0.053 −2394.581 928.655
Presubiculum 0.147 0.196 0.016 −1399.802 958.286
Parasubiculum 0.784 0.940 0.001 −268.661 975.640
Hippocampal tail 0.085 0.127 0.028 −1657.922 952.250
Hippocampal
ﬁssure
0.043 *0.086 0.027 −1952.554 952.076
Fimbria 0.996 0.996 0.000 −4.561 945.580
HATA 0.962 0.996 0.000 45.173 941.158
Left hippocampus
CA1 0.025 *0.060 0.045 −2129.952 935.255
CA2/CA3 0.038 *0.075 0.040 −1995.406 950.145
CA4 0.002 *0.013 0.082 −2860.001 914.747
Granule cell layer 0.001 *0.011 0.094 −3062.294 898.117
Molecular layer 0.003 *0.013 0.077 −2774.238 922.557
Subiculum 0.016 *0.049 0.052 −2284.700 934.863
Presubiculum 0.416 0.554 0.006 −787.328 963.220
Parasubiculum 0.473 0.568 0.005 679.613 944.346
Hippocampal tail 0.044 *0.075 0.038 −1935.976 946.996
Hippocampal
ﬁssure
0.105 0.158 0.025 −1581.2 968.023
Fimbria 0.525 0.573 0.004 619.043 971.228
HATA 0.994 0.994 0.000 −7.131 967.600
Each hippocampal volume was adjusted for intracranial volume, age, sex and
depression status. All regression analyses include seven population covariates,
derived from multidimensional scaling, to control for population stratiﬁcation.
Associations which survive FDR corrections are indicated with *. Abbreviations:
p-value: uncorrected p-value; q-value: FDR-corrected p-value; R2: amount of
variance explained by the respective optimal PRS; β: regression coeﬃcient; SE:
standard error.
Fig. 2. Visual representation of the predictive
ability of the best-ﬁt PRS for estradiol on hip-
pocampal subﬁeld volume. A. Example sa-
gittal, axial and coronal cross-sections of the
human hippocampus segmented from an ex-
ample MRI image using FreeSurfer and colour-
coded to indicate each hippocampal subﬁeld.
B. For each hemisphere and subﬁeld combi-
nation, the results of the linear regression are
represented in a scale of dark blue (β=−0.4),
through white (β=0), to dark red (β=0.4) for
the beta coeﬃcient, and green to white for the
FDR-corrected q-value. Relationships which
did not survive the FDR correction are re-
presented in grey (q> 0.1). The six ﬁgures to
the left relate to the left hippocampus, and the
six ﬁgures to the right relate to the right hip-
pocampus. Relative hippocampal subﬁeld
structure is for visualisation only and is not
representative of all participants. The numer-
ical data is available in Table 3.
Table 4
Table showing the results of regressions that test the predictive ability of best-ﬁt
PRS for estradiol and hippocampal volume on case control status for either
postpartum depression of major depressive disorder in males and females. All
regression analyses include seven population covariates, derived from multi-
dimensional scaling, to control for population stratiﬁcation.
Depressive disorder P Adj. R2 β SE
PPD vs all controls 0.121 0.00282 −1211.691 782.234
PPD vs female controls 0.179 0.00266 −1076.882 802.015
MDD vs all controls 0.595 0.00008 169.200 318.049
Female MDD vs female controls 0.624 0.00005 193.213 393.920
Male MDD vs male controls 0.807 0.00011 132.561 542.234
Abbreviations: PRS: polygenic risk score; Adj. R2: amount of variance explained
by the respective optimal; β: regression coeﬃcient; SE: standard error; PPD:
postpartum depression; MDD: major depressive disorder.
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(Arevalo et al., 2015). Without fully understanding the cellular me-
chanism linking estradiol PRS to hippocampal volume observed in this
study, we cannot say whether our ﬁndings are relevant to these ther-
apeutic interventions.
We do not observe an association between PRSs for testosterone,
progesterone or prolactin and hippocampal volume in our study.
Compared to estradiol, the evidence for an association between hip-
pocampal volume and these other reproductive hormones is far weaker.
While there is some evidence that plasma testosterone correlates with
hippocampal volume, this has only been conducted in males and tends
to be in disease, elderly or medicated states (Foland-Ross et al., 2019;
Panizzon et al., 2010; Wainwright et al., 2011). There are very few
human studies investigating the role of progesterone or other progestins
in hippocampal volume and many studies are confounded by con-
current changes in estradiol levels (Pletzer et al., 2018). Furthermore, it
appears that endogenous progesterone compared to synthetic proges-
tins have very diﬀerent impacts on the brain (Chan et al., 2014). Like
progesterone, the link between plasma prolactin and the hippocampus
has not been properly investigated in humans. While there is a large
body of work suggesting that prolactin can impact the rodent hippo-
campus at the cellular level (Cabrera-Reyes et al., 2017; Carretero et al.,
2018; Morales et al., 2014), this does not appear to translate to any
change in whole hippocampal volume (Torner et al., 2009). There is
evidence from animal and cellular models that reproductive hormones
can inﬂuence the hippocampus at the cellular level through changes in
AHN, cell survival or branching (Chan et al., 2014; Morales et al., 2014;
Ransome and Boon, 2015), therefore it is possible that this may also
occur in humans without aﬀecting whole hippocampal volume.
In the context of MDD and PPD, PRS for estradiol did not directly
relate to case-control status. This suggests that although estradiol could
be one factor accounting for hippocampal volume reductions commonly
observed in psychiatric patients, it does not directly predict case-control
status. Consequently, it may be interesting to test if the estradiol PRS
predicts other diseases in which the hippocampus has been linked, for
example schizophrenia (Riecher-Rössler, 2017). This idea is supported
by the observed link between estradiol PRS and hippocampal subﬁelds
such as the CA regions, subiculum and dentate gyrus in our study,
which are commonly atrophied in a variety of psychiatric and degen-
erative disorders (Arnold et al., 2015; Hanseeuw et al., 2011; Haukvik
et al., 2015; Papiol et al., 2017). Our negative result suggests that
baseline estradiol levels may not play a causal role in depression, but
this is not to say that estradiol is not involved in the development of
depressive disorders. We acknowledge that inter-individual variation
explaining estradiol levels in our base cohort may be diﬀerent from
those during pregnancy or other life events when plasma estradiol
changes signiﬁcantly. Additionally, environmental factors such as
breastfeeding, parity or the drop following parturition may be more
pertinent in moderating reproductive hormones in the peripartum
period than genetic contributors (Bonnar et al., 1975; Schock et al.,
2016; Zhang et al., 2016). Our approach also utilized a stable, genetic
predictor of hormone levels and therefore ignores any hormonal ﬂuc-
tuations that occur throughout the lifespan and are thought to con-
tribute to depressive states (Gordon et al., 2016). Furthermore, inter-
individual variation in response to altered hormone levels, which are
not considered here, have been shown to contribute to depressive dis-
orders (Bloch et al., 2000).
Despite the important ﬁndings detailed here, our study has three
key limitations. Firstly, the accuracy of the PRS is subject to the power
of both the original GWAS and our target datasets. Although the ori-
ginal GWAS was the largest to-date, it is likely still underpowered, and
consequently our PRS may lack predictive power. Furthermore, the
neuroimaging dataset and PPD subsets are small, which may mean we
are unable to detect smaller eﬀect sizes in our sample. In addition, our
neuroimaging cohort consisted of both healthy and depressed in-
dividuals. Although we detected no diﬀerences in volume between
those who had and had not been on antidepressants within the last six
months, we were underpowered to test the eﬀects of individual drug
types and treatment durations, which have been linked to changes in
hippocampal volume (Boldrini et al., 2013). Additionally, we lacked
information on factors such as menstrual stage, menopause or hormonal
medications, which may also impact hippocampal volume (Barth et al.,
2016; Bayer et al., 2013). Secondly, although PRSs are commonly used
in Mendelian randomization designs and genetic epidemiology
(Dudbridge, 2013; Papiol et al., 2017; Peyrot et al., 2014), they may be
subject to the eﬀects of horizontal pleiotropy; whereby a subset of SNPs
included in the PRS predict variance for another related trait, driving
the observed association (Dudbridge, 2013). Although horizontal
pleiotropy is possible, it’s important to note that at the protein level,
estradiol is correlated with testosterone (Ruth et al., 2016), which did
not predict hippocampal volume in our study; supporting the view that
the eﬀect may be uniquely related to estradiol. In the future, inference
of causality can be made more certain once more powerful GWASs are
performed and replicable genome-wide signiﬁcant association hits can
be used as an instrumental variable to probe the direction of association
between estradiol and hippocampal volume. Finally, the deﬁnition of
PPD within this study was made retrospectively using a subset of the
MDD cohort. We therefore may be missing other PPD cases due to in-
suﬃcient information (e.g. where pregnancy aligned to the third most
severe depressive episode, which was not captured). Additionally, for
our PPD analysis we used a control population which did not exclude
women who had not experienced a pregnancy and therefore could not
have experienced PPD. We did this primarily due to a small sample size
and missing data in our control sample on whether females had ex-
perienced a previous pregnancy. Subsequently, because the risk for PPD
is relatively low on the population level, we included all female RA-
DIANT controls in order to achieve the best power possible. We ac-
knowledge that screened controls would have made for a more ideal
comparison group.
5. Conclusions
Our study employed novel genetic and neuroimaging analyses
which provide new insight into the regulation of hippocampal volume
by estradiol. Our work suggests genetic risk for higher estradiol levels
predict smaller hippocampal volumes, possibly mediated via changes to
AHN in the neurogenic regions of the hippocampus. Genetic risk for
higher estradiol levels was not, however, associated with risk for de-
veloping MDD or PPD. Future studies should aim to replicate our
ﬁndings in larger samples, test the generalizability of the ﬁndings
outside of the European population, and examine whether estradiol’s
eﬀects on the hippocampus moderate risk for diseases other than de-
pression.
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